Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

More Patient Deaths Put Hold on Juno’s CAR-T Immunotherapy Clinical Trial

XTALKS VITALS NEWS

CAR-T

The Phase II clinical trial of Juno’s JCAR015 – named ROCKET – was voluntarily placed on hold following the adverse events.

Share this!

November 29, 2016 | by Sarah Hand, M.Sc.

Biopharmaceutical company Juno Therapeutics, has announced that more patients participating in their CAR-T immunotherapy clinical trial, have died as a result of the treatment. Two patients suffered severe cerebral edema – swelling of the brain – which led to the death of one patient, and the prediction that the other will not recover.

The Phase II clinical trial of Juno’s JCAR015 – named ROCKET – was voluntarily placed on hold following the adverse events. Just a few months ago, three patients with relapsed or refractory B cell acute lymphoblastic leukemia died during the course of the study, prompting the US Food and Drug Administration (FDA) to enforce a temporary clinical hold while the deaths were investigated.

Juno quickly identified a specific chemotherapy drug, fludarabine, as the cause of the patient deaths, which was used as a pre-conditioning treatment before the CAR-T cell therapy was administered. However, even after removing this drug from the study protocol after resuming the trial, the ROCKET trial has still been plagued by more patient deaths.

It is our view that the removal of fludarabine has reduced the incidence of severe neurotoxicity,” said Hans Bishop, CEO of Juno Therapeutics in a conference call regarding the trial last week. “It just hasn’t gotten us as far as we hoped that it would.”



Now that five patient deaths have been associated with the CAR-T immunotherapy trial, Juno is sure to face many questions regarding the safety of JCAR015. As the FDA was the one to allow the clinical trial to continue following the first deaths, the regulatory agency will likely face increased scrutiny over the coming weeks.

“It’s just terrible,” Brad Loncar, founder of a cancer immunotherapy fund, told Stat News. “They’ve killed a couple of people, and it seems like, in part, it’s because of the rush to judgment.”

According to Bishop, the patients participating in the ROCKET trial were already suffering the effects of the rare, but highly-lethal form of blood cancer before joining the study. As Juno still has other CAR-T clinical trials on the go, they could still meet their target of launching their first therapeutic by 2018.


Keywords: CAR-T, Immunotherapy, Clinical Trials


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.